LCG
DYN icon

Lisanti Capital Growth’s Dyne Therapeutics DYN Stock Holding History

Lisanti Capital Growth’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-154,445
Closed -$3.02M – 121
2025
Q4 		$3.02M Buy
+154,445
New +$2.92M 0.72% 68
2025
Q1 		– Sell
-57,755
Closed -$1.36M – 124
2024
Q4 		$1.36M Buy
57,755
+40,445
+234% +$1.2M 0.33% 93
2024
Q3 		$622K Sell
17,310
-88,830
-84% -$3.54M 0.16% 112
2024
Q2 		$3.75M Buy
106,140
+19,530
+23% +$568K 0.9% 55
2024
Q1 		$2.46M Buy
+86,610
New +$1.96M 0.6% 70

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Lisanti Capital Growth's DYN Position: Q1 2026 in Review

Lisanti Capital Growth sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 154,445 shares — an estimated $3.02M sold.

Lisanti Capital Growth first reported a position in DYN in Q1 2024 and held it in 5 quarters. The position peaked at $3.75M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Lisanti Capital Growth reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Lisanti Capital Growth sold 154,445 Dyne Therapeutics shares in Q1 2026, an estimated $3.02M.
  • Lisanti Capital Growth first reported a position in Dyne Therapeutics in Q1 2024 and held it in 5 quarters.
  • Lisanti Capital Growth's Dyne Therapeutics position peaked at $3.75M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Lisanti Capital Growth's 13F filing for Q1 2026, filed 7 May 2026.